CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
HPV OncoPredict is a diagnostic device designed to detect high-risk Human Papillomavirus (hrHPV) in cervical samples. It enables early identification of women at risk for cervical cancer, allowing for timely intervention and potentially replacing traditional Pap smears in screening programs.
Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development.
It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early.
Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology…
GENEFIRST LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Milan
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
